BOOG Plenair 9 maart 2021
43ste vergadering Borstkanker Onderzoek Groep (BOOG)
Presentaties zijn na inloggen te vinden onderaan deze pagina
Algemene zaken
15.00 uur Welkom en mededelingen, dr. A. Jager, Voorzitter BOOG
15.05 uur BOOG Algemeen, dr. A.E. van Leeuwen-Stok, BOOG SC
Deel 1: Locoregionale en (Neo)adjuvante behandeling
Moderatoren: dr. J. Heijns (Amphia) en drs. C. van der Pol (Alrijne)
WG portefeuillehouders BOOG bestuur
WG neo-adjuvant
15.15 u Presentatie dr. J.R. Kroep (LUMC)
Update TRAIN-3, NEOLBC en DATA
DIRECT-2 voorstel
Farma feasibilities:
GSK feasibility: A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either Triple-Negative Breast Cancer or HER2-neg BRCAmut Breast - Cancer with Molecular Disease Based on Circulating Tumor DNA Levels after Definitive Therapy.
15.30 u ENDO-67 S. Buijs, MSc (EMC)
15.40 u TRAIN-4 en translationele TRAIN-2, analyses prof.dr. G. Sonke, (NKI-AVL)
15.50 u Immunotherapie bij TNBC, dr.M. Kok (NKI-AVL)
16.00 u DIRECT Effect – translationeel bij DIRECT, P.Lee Meeuw Kjoe, MSc (UMCU)
WG locoregionaal
16.10 u Presentatie dr. GJ Liefers (LUMC)
LORD, TOP-2, INDAX
16.20 u UMBRELLA, prof.dr. H.M. Verkooijen (UMCU)
16.35 u DESCARTES dr. F van Duijnhoven (NKI-AVL)
16.45 – 16.55 u PAUZE
Deel 2: Klinische diagnostiek en Gemetastaseerde ziekte
Moderatoren: dr. V. Dezentjé (NKI-AVL) en prof.dr. H.M. Verkooijen (UMCU)
WG portefeuillehouders BOOG bestuur
WG Diagnostiek
16.55 u DENSE mammae en screening, dr.R. Mann (RadboudUMC en NKI-AVL)
17.05 u Artifcial Intelligence in klinische diagnostiek studies, dr.R. Mann (RadboudUMC en NKI-AVL)
WG Gemetastaseerde ziekte
17.15 u Presentatie Monique Bos:
Actuele status lopende studies
SONIA – TRIPLE-B – TIBET
Stand van zaken feasibilities / site selecties:
BIG ALPHABET
A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer
TROPION-Breast01
Phase 3, randomized, Her2-negative breast cancer, Dato-Dxd vs chemo )AZ led)
TROPION-breast01 - Patients with Triple Negative Breast Cancer and Hormone Receptor-Positive HER2-Negative Patients with metastatic breast cancer with HER2 mutations who have no satisfactory therapy (D9268C0001)
EMBER-3 Efficacy of A Novel SERD in Participants with ER+ / HER2- metastatic Breast Cancer Compared to fulvestrant or exemestane (Lilly, oral SERD)
Stand van zaken opstartende farma studies
AMEERA-5 (Sanofi EFC15935 SERD)
A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer
who have not received any prior systemic anti-cancer treatment for advanced disease
DESTINY-Breast 06 (AstraZeneca)
Phase III Study of DS-8201 versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive, Breast Cancer Patients who have Progressed On Endocrine Therapy in the Unresectable or Metastatic Setting (D9670C00001)
DESTINY-Breast 05, 10 en 11
17.40 u SEQUEL-Breast dr. V Dezentjé (NKI-AVL)
17.55 u Afsluiting dr. A. Jager